ライフサイエンスコーパス: LNP

1 LNP cells were also associated with changes to signaling

2 LNP composition is based upon clinically relevant formul

3 LNP is also required for infection by the mycorrhizal fu

4 LNP is present on the surface of the root hairs, and tre

5 LNP-dsP21-322-2'F treatment also facilitates p21 activat

6 LNPs containing OA is a promising nanocarrier system for

7 LNPs treated with mouse serum showed higher levels of si

8 LNPs were incubated with 50% serum from different specie

9 d as markedly lactose intolerant (S-LNP), 13 LNP subjects who denied lactose intolerance (A-LNP), and

10 gnificantly from 2.5 (95% CI 1.8-3.3) at 15% LNP to 1.3 (1.2-1.9; p=0.014) at 40% LNP.

11 Inventory 2 (MMPI-2) was administered to 19 LNP subjects self-described as markedly lactose intolera

12 at 15% LNP to 1.3 (1.2-1.9; p=0.014) at 40% LNP.

13 P subjects who denied lactose intolerance (A-LNP), and 10 lactase-persistent individuals who believed

14 ntly greater gaseous symptoms than did the A-LNP subjects during both treatment periods.

15 amine 2000, a commercial transfection agent, LNPs containing OA delivered microRNA-122 in a more effi

16 orm of the non-parametric nonlinearity in an LNP model.

17 b self-amplifying RNA encapsulated within an LNP substantially increased immunogenicity compared with

18 ell as the cluster-associated genes Evx2 and LNP, in the paddlefish Polyodon spathula, a basal ray-fi

19 Both 2'-fluoro modification and LNP formulation also improve duplex stability in urine.

20 because of the high rate of dissimulation by LNP subjects.

21 ining family O member 1 (Plekho1) siRNA (CH6-LNPs-siRNA).

22 RNA targeting catenin beta 1 (CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffere

23 se in tumor burden was evident in the CTNNB1-LNP group versus all controls, which was associated with

24 Db-LNP is also present in the root pericycle where its leve

25 Db-LNP is present on the surface of young and emerging root

26 Maximum levels of Db-LNP are found in 2-d-old roots, and the expression of th

27 ain a lectin/nucleotide phosphohydrolase (Db-LNP) that binds to the Nod factor signals produced by rh

28 In this study we show that Db-LNP is differentially distributed along the surface of t

29 hese results support the possibility that Db-LNP is involved in the initiation of the Rhizobium legum

30 Over the past three decades, LNP proportion has increased, mainly reflecting enhanced

31 drugs that are highly pure and well-defined, LNP drug products can exhibit heterogeneity in size, com

32 specifically designed for hepatic delivery, LNPs containing OA showed comparable liver accumulation

33 al protein production in the spleen, despite LNPs being observed transiently in the liver and other o

34 treatment with LNP-formulated dsP21-322-2'F (LNP-dsP21-322-2'F) or one of its nonformulated variants.

35 cularly for those whose tumors contained few LNP cells.

36 he discovery of next-generation reagents for LNP-mediated nucleic acid delivery.

37 , greater than 50% mFXN protein derived from LNPs was detected seven days after intravenous administr

38 lated that the amount of siRNA released from LNPs after going through these treatments can be used as

39 The amount of siRNA released from LNPs was determined using spectrophotometry employing th

40 t osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strateg

41 Furthermore, LNP-Tmprss6 siRNA treatment of Hbb(th3/+) mice substanti

42 liver homogenates demonstrated efficient FXN LNP uptake in hepatocytes and revealed that the mitochon

43 days after intravenous administration of FXN LNPs, suggesting that the half-life of mFXN in vivo exce

44 Moreover, when FXN LNPs were delivered by intrathecal administration, we de

45 ing T cells was observed in tumors with high LNP cell counts.

46 Importantly, LNPs were also able to boost DEN-80E specific CD4+ and C

47 w and meta-regression to quantify changes in LNP over time and the impact of this change on survival

48 o successfully develop and ensure quality in LNP pharmaceuticals.

49 signaling responses could be reactivated in LNP cells, indicating that BCR signaling is not missing

50 not explain the absence of BCR signaling in LNP tumor cells, and other signaling responses were inta

51 11 studies with prognostic data, increasing LNP was associated with improved overall survival in bot

52 an FIX (hFIX) mRNA encapsulated in our LUNAR LNPs results in a rapid pulse of FIX protein (within 4-6

53 We introduce a new method (LNP) that reports reasonable p-values and also detects m

54 Two doses of modified mRNA LNPs encoding prM-E genes that produced virus-like parti

55 ta demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable protective immunity and th

56 -encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane and envelope glycoprotein

57 with 30 mug of nucleoside-modified ZIKV mRNA-LNP protected mice against ZIKV challenges at 2 weeks or

58 Here, we generated mRNA-LNPs by incorporating HPLC purified, 1-methylpseudouridi

59 injected with 0.005-0.250mg/kg doses of mRNA-LNPs by 6 different routes and high levels of protein tr

60 acheal deliveries led to trafficking of mRNA-LNPs systemically resulting in active translation of the

61 The development of lipid nanoparticle (LNP) based small interfering RNA (siRNA) therapeutics pr

62 therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein-targeting (NP-ta

63 We engineered a lipid nanoparticle (LNP) encapsulated modified mRNA vaccine encoding wild-ty

64 ological evaluation of a lipid nanoparticle (LNP) system that can encapsulate mRNA, navigate to the s

65 P35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulatio

66 were formulated in a lipidoid nanoparticle (LNP).

67 ve (dsP21-322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

68 atenin mice with EnCore lipid nanoparticles (LNP) loaded with a Dicer substrate small interfering RNA

69 Here, we designed lipid-based nanoparticles (LNPs) coated with anti-CD38 monoclonal antibodies that a

70 een developed for lipid-based nanoparticles (LNPs) for delivery of siRNA and microRNA (miRNA).

71 Lipid nanoparticles (LNPs) are efficient carriers for short-interfering RNAs

72 alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable of delivering human mRNA with unprecedente

73 aptamer-functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domai

74 uality siRNA-containing lipid nanoparticles (LNPs) for a large number of materials, we have shown tha

75 r in vivo evaluation of lipid nanoparticles (LNPs) for systemic small interfering RNA (siRNA) deliver

76 ss6 siRNA formulated in lipid nanoparticles (LNPs) that are preferentially taken up by the liver woul

77 h for the evaluation of lipid nanoparticles (LNPs) to identify relationships between structure, biolo

78 l mRNA delivery through lipid nanoparticles (LNPs) to treat a Factor IX (FIX)-deficient mouse model o

79 NA (siRNA) delivered in lipid nanoparticles (LNPs) using cellular trafficking probes in combination w

80 XN mRNA, in the form of lipid nanoparticles (LNPs), was administered intravenously in adult mice.

81 ering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine.

82 with ionizable cationic lipid nanoparticles (LNPs).

83 The results showed that neither LNP group had a significant increase in symptoms (P < 0.

84 egligible symptoms in lactase-nonpersistent (LNP) individuals self-described as being severely lactos

85 der cancer by intravesical administration of LNP-formulated RNA duplexes.

86 that permits the high-resolution analysis of LNP size distribution in its native solution condition.

87 Intravesical delivery of LNP-dsP21-322-2'F into mouse bladder results in urotheli

88 of LNP pKa as one of the key determinants of LNP function and activity both in vitro and in vivo.

89 ple parameters enabled the identification of LNP pKa as one of the key determinants of LNP function a

90 Here, we show that antisense inhibition of LNP blocks nodulation in Lotus japonicus.

91 regulator of the major recycling pathways of LNP-delivered siRNAs.

92 In 20 studies, across a range of LNP proportions from 15% to 40%, the hazard ratios for o

93 ful prescreening tool for the advancement of LNPs in vivo.

94 rk can help to facilitate the development of LNPs as a well-defined pharmaceutical product.

95 siRNA undergoes exocytosis through egress of LNPs from late endosomes/lysosomes.

96 s are required for initial cellular entry of LNPs through macropinocytosis, including proton pumps, m

97 rategy is to mimic the in vivo experience of LNPs after systemic administration, such as interactions

98 scientific knowledge in the heterogeneity of LNPs as well as high-resolution techniques that permit t

99 molecular weight, and siRNA cargo loading of LNPs could be achieved.

100 ever, little is known about the potential of LNPs to deliver mRNA.

101 can be broadly applied to a diverse range of LNPs.

102 nt cells show enhanced cellular retention of LNPs inside late endosomes and lysosomes, and increased

103 rovides similar size distribution results on LNPs compared to FFF.

104 icle assembly process, it was found that one LNP (A) possessed a narrow size and molecular weight dis

105 assay was developed to screen and rank order LNPs for in vivo evaluation.

106 entified LECTIN NUCLEOTIDE PHOSPHOHYDROLASE (LNP) as a Nod factor-binding protein.

107 This lectin-nucleotide phosphohydrolase (LNP) has a substrate specificity characteristic of the a

108 s to delivery such as siRNA entrapment, pKa, LNP stability, and cell uptake as a collective may serve

109 he parameters of a linear-nonlinear-Poisson (LNP) model, and that the empirical single-spike informat

110 a of the anus (SCCA), lymph node positivity (LNP) indicates poor prognosis for survival and is centra

111 ct measurement of intra-lymph node pressure (LNP) demonstrated a decrease in expanding PLN versus WT

112 These lymphoma negative prognostic (LNP) cells increased as tumors relapsed following chemot

113 radiotherapy as the main treatment, reported LNP proportions (all studies), and reported overall surv

114 We identified 62 studies reporting LNP proportions, which included 10 569 patients.

115 Two representative LNPs with similar bulk properties were evaluated in-dept

116 S-LNP subjects have underlying flatulence that is misattri

117 high score on the "lie" validity scale for S-LNP subjects.

118 However, S-LNP subjects reported significantly greater gaseous symp

119 -described as markedly lactose intolerant (S-LNP), 13 LNP subjects who denied lactose intolerance (A-

120 CTNNB1; CTNNB1-LNP), scrambled sequence (Scr-LNP), or phosphate-buffered saline for multiple cycles.

121 eated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected m

122 with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four

123 Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5 days post-challenge.

124 VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when

125 Six LNPs with sizes in the rang of 60-140 nm were evaluated

126 don-optimized firefly luciferase into stable LNPs.

127 We hypothesized that such LNP individuals could also tolerate two cups of milk per

128 with siRNAs against cyclin D1, CD38-targeted LNPs induced gene silencing in MCL cells and prolonged s

129 ontrol of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this

130 We conclude that LNP subjects tolerate two cups of milk per day without a

131 These results demonstrate that LNP composition alone can be used to modulate the site o

132 In the present study, we demonstrate that LNP-Tmprss6 siRNA treatment of Hfe(-/-) and Hbb(th3/+) m

133 s to gene ontology annotations and find that LNP is more sensitive than the three previous methods.

134 n together, these observations indicate that LNP acts at a novel position in the early stages of symb

135 We propose that LNP functions at the earliest stage of the common nodula

136 The present results suggest that LNP drug products are highly complex and diverse in natu

137 fungus Glomus intraradices, suggesting that LNP plays a role in the common signaling pathway shared

138 Our results demonstrate that LNPs are appropriate carriers for mRNA in vivo and have

139 pigs, and in Rhesus macaques, revealed that LNPs induced high titers of Dengue virus neutralizing an

140 tokine and chemokine profiling revealed that LNPs induced strong chemokine responses without signific

141 The LNP method is based on a log-normal prior on the distrib

142 ctor did induce root hair deformation in the LNP antisense lines.

143 id (OA), an unsaturated fatty acid, into the LNP formulation significantly enhanced the delivery effi

144 portance of "helper lipid" components of the LNP formulation on the cellular uptake and transfection

145 tramuscular and intradermal injection of the LNP-encapsulated mRNA translated locally at the site of

146 hting the crucial role for the charge of the LNP.

147 of the nanoparticle dramatically reduced the LNP's ability to boost DEN-80E specific immune responses

148 used this new observation to infer that the LNP proportions of more than 30% seen in modern clinical

149 For the LNPs used in this work, the evaluation of multiple param

150 Both the existence of these LNP cells and their aberrant signaling profiles provide

151 Importantly, this LNP induces more than 85% of total protein production in

152 rs, and treatment of roots with antiserum to LNP inhibits their ability to undergo root hair deformat

153 an year since 2007) are higher than the true LNP proportion.

154 scenarios reproduced this effect if the true LNP proportions were 20% or 25%, but not if the true LNP

155 ortions were 20% or 25%, but not if the true LNP proportions were 30% or greater.

156 ation might occur, we simulated varying true LNP proportions and true overall survival, and compared

157 not only serve as a method for understanding LNP product property, permitting control on product qual

158 Symptoms were recorded when LNP subjects ingested 240 mL regular or lactose-hydrolyz

159 10(-30) on 1/1000 uncorrelated pairs, while LNP reports significance correctly.

160 apoptosis in vitro following treatment with LNP-formulated dsP21-322-2'F (LNP-dsP21-322-2'F) or one